Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M1 muscarinic receptors

Movement Disorders

Volumn 29, Issue 13, 2014, Pages 1655-1665

  Maltese, Marta ^a,b   Martella, Giuseppina ^a,b   Madeo, Graziella ^a,b   Fagiolo, Irene ^a,b   Tassone, Annalisa ^a,b   Ponterio, Giulia ^a,b   Sciamanna, Giuseppe ^a,b   Burbaud, Pierre ^c   Conn, P Jeffrey ^d   Bonsi, Paola ^b   Pisani, Antonio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dystonia; Muscarinic receptor antagonists; Striatum; Synaptic plasticity

Indexed keywords

CHAPERONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DYT1 PROTEIN, MOUSE;

ANIMAL; BIOPHYSICS; CORPUS STRIATUM; CYTOLOGY; DRUG EFFECTS; ELECTROSTIMULATION; EXCITATORY POSTSYNAPTIC POTENTIAL; GENETICS; IN VITRO STUDY; LONG TERM POTENTIATION; MOUSE; MUTATION; NERVE CELL; PATCH CLAMP TECHNIQUE; SYNAPSE; THALAMUS; TRANSGENIC MOUSE;

ANIMALS; BIOPHYSICS; CHOLINERGIC ANTAGONISTS; CORPUS STRIATUM; ELECTRIC STIMULATION; EXCITATORY POSTSYNAPTIC POTENTIALS; IN VITRO TECHNIQUES; LONG-TERM POTENTIATION; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; MUTATION; NEURONS; PATCH-CLAMP TECHNIQUES; SYNAPSES; THALAMUS;

EID: 84911196137     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26009     Document Type: Article

References (47)

1. Ghilardi MF, Carbon M, Silvestri G, et al. Impaired sequence learning in carriers of the DYT1 dystonia mutation. Ann Neurol 2003;54:102-109.
2. Edwards MJ, Huang YZ, Mir P, et al. Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. Mov Disord 2006;21:2181-2186.
3. Quartarone A, Pisani A. Abnormal plasticity in dystonia: disruption of synaptic homeostasis. Neurobiol Dis 2011;42:162-170.
4. Martella G, Tassone A, Sciamanna G, et al. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain 2009;132:2336-2349.
5. Grundmann K, Glöckle N, Martella G, et al. Generation of a novel rodent model for DYT1 dystonia. Neurobiol Dis 2012;47:61-74.
6. Martella G, Maltese M, Nisticò R, et al. Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. Neurobiol Dis 2014;65:124-132.
7. Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5:864-872.
8. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007;6:721-733.
9. Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2009;30:148-155.
10. Hersch SM, Gutekunst CA, Rees HD, et al. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 1994;14:3351-3363.
11. Bonsi P, Martella G, Cuomo D, et al. Loss of muscarinic autoreceptor function impairs long-term depression, but not long-term potentiation in the striatum. J Neurosci 2008;28:6258-6263.
12. Xiang Z, Thompson AD, Jones CK, et al. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. J Pharmacol Exp Ther 2012;340:595-603.
13. Sheffler DJ, Williams R, Bridges TM, et al. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol 2009;76:356-368.
14. Goodchild RE, Kim CE, Dauer WT. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 2005;48:923-932.
15. Calabresi P, Pisani A, Mercuri NB, et al. Long-term potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur J Neurosci 1992;4:929-935.
16. Sciamanna G, Bonsi P, Tassone A, et al. Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. Neurobiol Dis 2009;34:133-145.
17. Schulz PE, Cook EP, Johnston D. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. J Neurosci 1994;14:5325-5337.
18. Wang Z, Kai L, Day M, et al. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006;50:443-452.
19. Rioult-Pedotti MS, Donoghue JP, Dunaevsky A. Plasticity of the synaptic modification range. J Neurophysiol 2007;98:3688-3695.
20. Kornhuber J, Parsons CG, Hartmann S, et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist:binding and patch clamp studies. J Neural Transm Gen Sect 1995;102:237-246.
21. Calabresi P, Centonze D, Gubellini P, et al. Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. Eur J Neurosci 1998;10:2887-2895.
22. Yan Z, Surmeier DJ. Muscarinic (m2/m4) receptors reduce N- and P-type Ca2+ currents in rat neostriatal cholinergic interneurons through a fast membrane-delimited, G-protein pathway. J Neurosci 1996;2592-2604.
23. Pancani T, Bolarinwa C, Smith Y, et al. M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses. ACS Chem Neurosci 2014;5:318-324.
24. Kawaguchi Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J Neurosci 1993;13:4908-4923.
25. Sciamanna G, Tassone A, Mandolesi G, et al. Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia. J Neurosci 2012;32:11991-12004.
26. Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;2:CD003735.
27. Pisani A, Bernardi G, Ding J, et al. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 2007;30:545-553.
28. Bolam JP, Wainer BH, Smith AD. Characterization of cholinergic interneurons in the rat neostriatum: A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. Neuroscience 1984;12:711-718.
29. Everit BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol 1997;48:649-684.
30. Mink JW. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol 2003;60:1365-1368.
31. Sohn YH, Hallett M. Disturbed surround inhibition in focal hand dystonia. Ann Neurol 2004;56:595-599.
32. Dang MT, Yokoi F, Cheetham CC, et al. An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 ΔGAG knock-in mice. Behav Brain Res 2012;226:465-472.
33. Zhang W, Basile AS, Gomeza J, et al. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 2002;22:1709-1717.
34. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002;53:590-605.
35. Ding J, Guzman JN, Tkatch T, et al. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci 2006;9:832-842.
36. Bymaster FP, McKinzie DL, Felder CC, et al. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 2003;28:437-442.
37. Galarraga E, Hernandez-Lopez S, Reyes A, et al. Cholinergic modulation of neostriatal output:a functional antagonism between different types of muscarinic receptors. J Neurosci 1999;19:3629-3638.
38. Shen W, Hamilton SE, Nathanson NM, et al. Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J Neurosci 2005;25:7449-7458.
39. Shen W, Tian X, Day M, et al. Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat Neurosci 2007;10:1458-1466.
40. Beatty JA, Sullivan MA, Morikawa H, Wilson CJ. Complex autonomous firing patterns of striatal low-threshold spike interneurons. J Neurophysiol 2012;108:2012.
41. Ibáñez-Sandoval O, Tecuapetla F, Unal B, Shah F, Koós T, Tepper JM. Electrophysiological and morphological characteristics and synaptic connectivity of tyrosine hydroxylase-expressing neurons in adult mouse striatum. J Neurosci 2010;30:6999-7016.
42. Pakhotin P, Bracci E. Cholinergic interneurons control the excitatory input to the striatum. J Neurosci 2007;27:391-400.
43. Calabresi P, Centonze D, Gubellini P, et al. Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. Neuropharmacology 1999;38:323-326.
44. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 2012;27:1205-1215.
45. Erosa-Rivero HB, Bata-García JL, Alvarez-Cervera FJ, et al. The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes. Neuropharmacology 2014;81:176-187.
46. Horn S, Comella CL. Treatment of dystonia. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders, 5th ed. Philadelphia, PA, Lippincott Williams & Wilkins, 2007; pp 348-355.
47. Lang AE, Lees A. Anticholinergic therapies in the treatment of Parkinson's disease. In: Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(Suppl. 4):S7-S12.